Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2018 Oct 23;18(1):3–16. doi: 10.1158/1535-7163.MCT-18-0863

Figure 4. PTC299 inhibits DHODH activity and reduces elevated VEGFA levels in patients with neurofibromatosis type 2.

Figure 4.

(A) Reduction in mean levels of serum VEGFA after 8 weeks of PTC299 treatment; Data are represented as mean ± SEM, n = 11. (B) VEGFA reduction for individual patients over the course of the PTC299 treatment; (C) Serum levels of DHO are correlated with PTC299 concentration in patient-002; (D) Serum levels of DHO are inversely correlated with serum VEGFA levels in patient-002. (E) PTC299 increases serum DHO in three additional patients whose serum samples were still available at the time of analysis. BLQ: below the level of quantification.